BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lumipodlin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lumipodlin\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07014137-2323@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270302
DTEND;VALUE=DATE:20270303
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT07014137)
DESCRIPTION:Lumipodlin\, phase 2.\nStudy: A Trial of ABSK043\, an Oral PD-L
 1 Inhibitor\, in Patients With Angiogenic Sarcomas\nEstimated primary comp
 letion: 2 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lumipodlin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07014137
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04964375-2323@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Lumipodlin: Phase 1 readout est. (NCT04964375)
DESCRIPTION:Lumipodlin\, phase 1.\nStudy: A Study to Assess Safety\, Tolera
 bility\, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid T
 umor\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lumipodlin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04964375
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668103-2323@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT06668103)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
 \nEstimated primary completion: 30 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lumipodlin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06668103
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164170-2323@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT07164170)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib\nE
 stimated primary completion: 30 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lumipodlin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07164170
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632262-2323@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT06632262)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of ABSK061 and ABSK043\nEstimated primary completion:
  30 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lu
 mipodlin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06632262
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710612-2323@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT07710612)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Study of ABSK043 Combined With Osimertinib\nEstimated primary comple
 tion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lumipodlin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07710612
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
